They expressed wild-type CDKN2A and had no family history of melanoma; Group 2 consisted of three FM mutation carriers with a V126D-p16 mutation (F1, F2, and F3); Group 3 consisted of three FM mutation carriers (F4, F5 and F6) with a R87P-p16 mutation. This evidence concerns the gene CDKN2A and melanoma.